These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 20863217)
1. Effects of L-Carnitine supplement on plasma coagulation and anticoagulation factors in hemodialysis patients. Hakeshzadeh F; Tabibi H; Ahmadinejad M; Malakoutian T; Hedayati M Ren Fail; 2010; 32(9):1109-14. PubMed ID: 20863217 [TBL] [Abstract][Full Text] [Related]
2. L-Propionyl carnitine, homocysteine and S-adenosylhomocysteine in hemodialysis. Perna AF; Acanfora F; Satta E; Lombardi C; Capasso R; Ingrosso D; De Santo NG J Nephrol; 2007; 20(1):63-5. PubMed ID: 17347975 [TBL] [Abstract][Full Text] [Related]
3. The effects of L-carnitine therapy on respiratory function tests in chronic hemodialysis patients. Bavbek N; Akay H; Uz B; Uz E; Turgut F; Kanbay M; Senes M; Akcay A; Duranay M Ren Fail; 2010 Jan; 32(2):157-61. PubMed ID: 20199175 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of the effect of intravenous l-carnitine on quality of life in chronic hemodialysis patients. Semeniuk J; Shalansky KF; Taylor N; Jastrzebski J; Cameron EC Clin Nephrol; 2000 Dec; 54(6):470-7. PubMed ID: 11140808 [TBL] [Abstract][Full Text] [Related]
5. The effects of L-carnitine on respiratory function tests in children undergoing chronic hemodialysis. Kavukçu S; Türkmen M; Salman S; Onvural B; Oktay G; Karaman O; Cevik NT Turk J Pediatr; 1998; 40(1):79-84. PubMed ID: 9673532 [TBL] [Abstract][Full Text] [Related]
6. Thrombophilic factors in Stage V chronic kidney disease patients are largely corrected by renal transplantation. Ghisdal L; Broeders N; Wissing KM; Mena JM; Lemy A; Wijns W; Pradier O; Donckier V; Racapé J; Vereerstraeten P; Abramowicz D Nephrol Dial Transplant; 2011 Aug; 26(8):2700-5. PubMed ID: 21285127 [TBL] [Abstract][Full Text] [Related]
7. Effects of carnitine supplementation on muscle metabolism by the use of magnetic resonance spectroscopy and near-infrared spectroscopy in end-stage renal disease. Vaux EC; Taylor DJ; Altmann P; Rajagopalan B; Graham K; Cooper R; Bonomo Y; Styles P Nephron Clin Pract; 2004; 97(2):c41-8. PubMed ID: 15218329 [TBL] [Abstract][Full Text] [Related]
8. Effects of L-carnitine supplementation on muscular symptoms in hemodialyzed patients. Sakurauchi Y; Matsumoto Y; Shinzato T; Takai I; Nakamura Y; Sato M; Nakai S; Miwa M; Morita H; Miwa T; Amano I; Maeda K Am J Kidney Dis; 1998 Aug; 32(2):258-64. PubMed ID: 9708610 [TBL] [Abstract][Full Text] [Related]
9. Effect of dialysate composition on the lipid response to L-carnitine supplementation. Zilleruelo G; Novak M; Hsia SL; Goldberg R; Abitbol C; Monkus E; Strauss J Kidney Int Suppl; 1989 Nov; 27():S259-63. PubMed ID: 2699997 [TBL] [Abstract][Full Text] [Related]
10. [Plasma l-carnitine in patients with chronic hemodialysis. II. Pharmacokinetics of l-carnitine and its replacement therapy in these patients]. Kudoh Y; Shoji T; Oimatsu H; Kikuchi K; Imura O; Watarai I Nihon Jinzo Gakkai Shi; 1984 Feb; 26(2):195-202. PubMed ID: 6748336 [No Abstract] [Full Text] [Related]
11. Pharmacokinetics of L-carnitine in patients with end-stage renal disease undergoing long-term hemodialysis. Evans AM; Faull R; Fornasini G; Lemanowicz EF; Longo A; Pace S; Nation RL Clin Pharmacol Ther; 2000 Sep; 68(3):238-49. PubMed ID: 11014405 [TBL] [Abstract][Full Text] [Related]
12. Carnitine metabolism in chronic renal failure. Acute effects of carnitine addition to the dialysate during acetate hemodialysis. Guarnieri G; Toigo G; Crapesi L; Situlin R; Del Bianco MA; Corsi M; Lo Greco P; Vasile A Contrib Nephrol; 1988; 65():1-23. PubMed ID: 3048873 [No Abstract] [Full Text] [Related]
13. Effects of L-carnitine on leukocyte function and viability in hemodialysis patients: A double-blind randomized trial. Thomas S; Fischer FP; Mettang T; Pauli-Magnus C; Weber J; Kuhlmann U Am J Kidney Dis; 1999 Oct; 34(4):678-87. PubMed ID: 10516349 [TBL] [Abstract][Full Text] [Related]
14. L-carnitine supplementation in the dialysis population: are Australian patients missing out? Reuter SE; Faull RJ; Evans AM Nephrology (Carlton); 2008 Feb; 13(1):3-16. PubMed ID: 18199095 [TBL] [Abstract][Full Text] [Related]
15. Carnitine metabolism in patients with chronic renal failure: effect of L-carnitine supplementation. Wanner C; Förstner-Wanner S; Rössle C; Fürst P; Schollmeyer P; Hörl WH Kidney Int Suppl; 1987 Oct; 22():S132-5. PubMed ID: 3480977 [No Abstract] [Full Text] [Related]
16. Insulin action on glucose and protein metabolism during L-carnitine supplementation in maintenance haemodialysis patients. Biolo G; Stulle M; Bianco F; Mengozzi G; Barazzoni R; Vasile A; Panzetta G; Guarnieri G Nephrol Dial Transplant; 2008 Mar; 23(3):991-7. PubMed ID: 18045815 [TBL] [Abstract][Full Text] [Related]
17. B vitamins and the risk of total mortality and cardiovascular disease in end-stage renal disease: results of a randomized controlled trial. Heinz J; Kropf S; Domröse U; Westphal S; Borucki K; Luley C; Neumann KH; Dierkes J Circulation; 2010 Mar; 121(12):1432-8. PubMed ID: 20231532 [TBL] [Abstract][Full Text] [Related]
18. Oxidized low-density lipoprotein biomarkers in patients with end-stage renal failure: acute effects of hemodialysis. Bossola M; Tazza L; Merki E; Giungi S; Luciani G; Miller ER; Lin EB; Tortorelli A; Tsimikas S Blood Purif; 2007; 25(5-6):457-65. PubMed ID: 18075247 [TBL] [Abstract][Full Text] [Related]
19. Serum levels of lipoprotein(a) and homocysteine in patients on hemodialysis who take hydroxymethylglutaryl-CoA reductase inhibitors, vitamin B6, and folic acid. Shojaei MH; Djalali M; Siassi F; Khatami MR; Boroumand MA; Eshragian MR Iran J Kidney Dis; 2009 Jul; 3(3):141-4. PubMed ID: 19617662 [TBL] [Abstract][Full Text] [Related]
20. Low total vitamin C plasma level is a risk factor for cardiovascular morbidity and mortality in hemodialysis patients. Deicher R; Ziai F; Bieglmayer C; Schillinger M; Hörl WH J Am Soc Nephrol; 2005 Jun; 16(6):1811-8. PubMed ID: 15814831 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]